Immatics NV Ordinary Shares IMTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
-
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
-
Immatics Announces Second Quarter 2024 Financial Results and Business Update
-
Immatics Appoints Alise Reicin to Board of Directors
-
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
-
Immatics shares rise on Moderna cancer collaboration
-
Immatics Shares Rise Premarket on Collaboration With Moderna
Trading Information
- Previous Close Price
- $10.52
- Day Range
- $10.13–10.51
- 52-Week Range
- $7.15–13.77
- Bid/Ask
- $10.35 / $10.36
- Market Cap
- $1.07 Bil
- Volume/Avg
- 481,136 / 320,506
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 343
- Website
- https://www.immatics.com
Comparables
Valuation
|
Metric
|
IMTX
|
MRUS
|
NAMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.61 | 4.59 | 4.05 |
Price/Sales | 12.69 | 83.22 | 204.31 |
Price/Cash Flow | — | — | — |
Price/Earnings
IMTX
MRUS
NAMS
Financial Strength
|
Metric
|
IMTX
|
MRUS
|
NAMS
|
|---|---|---|---|
Quick Ratio | 3.58 | 9.79 | 9.63 |
Current Ratio | 3.74 | 9.97 | 9.83 |
Interest Coverage | −109.38 | — | — |
Quick Ratio
IMTX
MRUS
NAMS
Profitability
|
Metric
|
IMTX
|
MRUS
|
NAMS
|
|---|---|---|---|
Return on Assets (Normalized) | −12.69% | −28.03% | −40.89% |
Return on Equity (Normalized) | −22.63% | −36.01% | −47.44% |
Return on Invested Capital (Normalized) | −26.37% | −38.75% | −50.04% |
Return on Assets
IMTX
MRUS
NAMS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pmvsrvcxr | Pbmhb | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vsbpzxv | Yspnmk | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Crqjspn | Jxqfrd | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qtbtwwxbq | Txvsyt | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Qljcndfsg | Lpj | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Kzgfmmfn | Mgxxz | $28.3 Bil | |||
| Moderna Inc
MRNA
| Ssjptlss | Lvy | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qkflzmtrf | Xqgjr | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zspfcymk | Kqtgwh | $13.3 Bil | |||
| Incyte Corp
INCY
| Nqmltvdt | Rgmvmdq | $13.0 Bil |
United States